-

Hemodialysis Technology Company Diality Names Robert Funari to its Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical technology company developing a smart, flexible hemodialysis platform, today announced the appointment of healthcare veteran Robert Funari to its board of directors.

Funari has spent nearly 50 years in the healthcare industry in public and privately held companies, in both services and medical devices. He has served as president and CEO of several companies, including Syncor International (acquired by Cardinal Health) and Crescent Healthcare, and as chairman or director of several companies, including Patient Care America and Beckman Coulter. He was chairman of hemodialysis technology company NxStage Medical until its 2019 acquisition by Fresenius Medical Care. At Baxter International, he held a variety of roles for nearly 20 years, ultimately serving as president of its Pharmaseal division.

“Robert has an outstanding, half-century record of bringing his knowledge and strategic thinking to bear on the constantly evolving healthcare market,” said Osman Khawar, MD, CEO of Diality. “His insights will be invaluable as we prepare to bring our new hemodialysis system to market to empower kidney care providers while prioritizing patient care and quality of life.”

Diality’s hemodialysis system is designed to be versatile enough for any care setting. Its compact footprint together with an intuitive user interface are intended to enable it to be easily integrated into – and transported within – any dialysis setting, be it acute-care hospital, dialysis clinic, transitional care unit, traditional home, or skilled nursing facility.

“Diality’s novel approach to developing an extremely flexible hemodialysis system interested me from the start,” added Funari. “I look forward to working with the strong leadership team Osman has assembled to help bring its mission of improving lives impacted by kidney disease to fruition.”

Diality also announced that Aaron Mishkin is leaving its board of directors.

“We thank Aaron for his dedicated service at Diality, and wish him well in his future endeavors,” Khawar said.

About Diality

Diality is a medical technology company developing a smart hemodialysis platform designed to be as capable and flexible as in-center treatment in an easy-to-use device that’s intended to be safe to operate in any environment. It offers versatility to enable healthcare providers to tailor treatment to each patient’s specific needs. The Diality system’s compact footprint and mobility are intended to enable it to be easily integrated into – and transported within – any dialysis setting, be it acute-care hospital, dialysis clinic, transitional care unit, traditional home, or skilled nursing facility. To learn more, please visit www.diality.com or find us on LinkedIn.

Disclaimer: This product is not yet available for use in the EU or US and is pending CE Mark and submission and clearance by the United States Food and Drug Administration. Performance claims referenced are development goals.

Diality


Release Versions

Social Media Profiles
More News From Diality

Diality Announces Three Poster Presentations During The American Society of Nephrology (ASN) Kidney Week 2025

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc. today announced that three posters highlighting new data from the first clinical use of the Moda-flx™ Hemodialysis System will be presented during the American Society of Nephrology’s Kidney Week 2025 in Houston, Texas. “Real-World Urea Clearance and Adequacy with the Moda-flx Hemodialysis System” proves the system’s ability to leverage 600mL/min dialysate flow rate to achieve weekly clearance and ultrafiltration targets from the standard three hemo...

Diality Announces First Patient Treated in Moda-flx Home IDE PRESCRIBE Diality Clinical Trial

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced the first patient treatment in its PRESCRIBE Diality Home Hemodialysis Clinical Trial in partnership with aQua Research Institute and aQua Dialysis in Houston, Texas. Diality is conducting the PRESCRIBE Diality trial under an Investigational Device Exemption (IDE) to evaluate a home use indication for the Moda-flx Hemodialysis System. The Moda-flx Hemodia...

Diality Names Dr. Chris Springer to Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company that has developed the Moda-flx Hemodialysis System™, today announced the addition of Dr. Chris Springer to its board of directors. Dr. Springer brings 30 years of commercial and strategic experience in the pharmaceutical and biotech industries to Diality. As Chief Strategy Officer for Vifor Pharma, he created a joint renal-drug company between Vifor Pharmaceuticals and Fresenius Medical Care as well as oversaw a series of...
Back to Newsroom